President Trump's plan for pharmaceutical tariffs seeks to enhance domestic production, yet it risks shaking up the supply chain and driving up drug prices. Industry leaders caution that these tariffs could worsen shortages and burden consumers. While companies like Bristol Myers Squibb are ready to invest heavily in the U.S., worries about regulatory challenges and market stability loom large.